NVAX stock forecast
Our latest prediction for Novavax, Inc.'s stock price was made on the Oct. 1, 2020 when the stock price was at 104.90$.
In the short term (2weeks), NVAX's stock price should underperform the market by -3.38%. During that period the price should oscillate between -11.74% and +11.23%.
In the medium term (3months), NVAX's stock price should underperform the market by -7.28%. During that period the price should oscillate between -41.81% and +25.73%.Get email alerts
Create a solid portfolio with NVAX
About Novavax, Inc.
Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
At the moment the company generates 919M USD in revenues.
On its last earning announcement, the company reported a loss of -9.74$ per share.
The book value per share is -0.23$
Three months stock forecastOct. 1, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|